Cogent Biosciences Ownership
| COGT Stock | USD 7.16 0.13 1.78% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 110.2 M | Current Value 110.5 M | Avarage Shares Outstanding 39.1 M | Quarterly Volatility 36.5 M |
Cogent |
Cogent Stock Ownership Analysis
About 100.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.94. Cogent Biosciences last dividend was issued on the 9th of November 2020. The entity had 1:4 split on the 9th of November 2020. Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cogent Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. For more info on Cogent Biosciences please contact Andrew MBA at 617 945 5576 or go to https://www.cogentbio.com.Besides selling stocks to institutional investors, Cogent Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cogent Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cogent Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Cogent Biosciences Quarterly Liabilities And Stockholders Equity |
|
Cogent Biosciences Insider Trades History
Less than 1% of Cogent Biosciences are currently held by insiders. Unlike Cogent Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cogent Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cogent Biosciences' insider trades
Cogent Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cogent Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cogent Biosciences backward and forwards among themselves. Cogent Biosciences' institutional investor refers to the entity that pools money to purchase Cogent Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 3024-12-31 | 3.9 M | Redmile Group, Llc | 2024-12-31 | 3.6 M | Octagon Capital Advisors Lp | 2.8 M | Deerfield Management Co | 2024-12-31 | 2.6 M | Geode Capital Management, Llc | 2024-12-31 | 2.3 M | Saturn V Capital Management Llc | 2024-12-31 | 1.5 M | Franklin Resources Inc | 2024-12-31 | 1.3 M | Vivo Capital, Llc | 2024-12-31 | 1.1 M | Sg Americas Securities, Llc | 2024-12-31 | 964.7 K | Fmr Inc | 2024-12-31 | 16.6 M | Kynam Capital Management, Lp | 2024-12-31 | 9.1 M |
Cogent Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cogent Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cogent Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cogent Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cogent Biosciences Outstanding Bonds
Cogent Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cogent Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cogent bonds can be classified according to their maturity, which is the date when Cogent Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| CCOI 7 15 JUN 27 Corp BondUS19240CAE30 | View | |
| US19240CAC73 Corp BondUS19240CAC73 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Cogent Biosciences Corporate Filings
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 27th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.